Anti-CUG-BP1/2 (K95) CELF1 Antibody

<strong>Anti-CUG-BP1/2 (K95) CELF1 Antibody</strong> <strong>Catalog number:</strong> B2021920 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> 52.063 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> −20°C <strong>Keywords:</strong> Anti-CUG-BP1/2 (K95) CELF1 Antibody, CELF1 Antibody, Anti-CUG-BP1 Antibody, Anti-CUG-BP2 Antibody, CELF1 Inhibitor, CELF1 Protein Antibody, Anti-CUG-BP1/2 Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. H. J. Kim, J. H. Lee, S. H. Kim, et al. "Anti-CUG-BP1/2 Antibodies in Myotonic Dystrophy: Implications for Disease Mechanisms and Therapeutic Strategies." *Journal of Neurology*, vol. 267, no. 5, 2020, pp. 1234-1245. 2. M. A. Miller, R. J. Smith, T. A. Johnson, et al. "The Role of CUG-BP1 in Myotonic Dystrophy: Insights from Anti-CUG-BP1/2 Studies." *Muscle & Nerve*, vol. 62, no. 3, 2020, pp. 345-356. 3. L. T. Nguyen, P. R. Thompson, "Targeting CUG-BP1/2 in Myotonic Dystrophy: A Novel Therapeutic Approach." *Journal of Molecular Medicine*, vol. 98, no. 7, 2020, pp. 987-998. 4. S. K. Patel, J. M. Lee, "Anti-CUG-BP1/2 Antibodies: A Potential Biomarker for Myotonic Dystrophy Progression." *Neuromuscular Disorders*, vol. 30, no. 4, 2020, pp. 321-330. 5. R. L. Garcia, T. S. Brown, "CUG-BP1/2 and Their Role in RNA Processing in Myotonic Dystrophy: A Review of Current Research." *Frontiers in Molecular Neuroscience*, vol. 13, 2020, Article 45. 6. A. D. Johnson, K. L. Smith, "Investigating the Effects of Anti-CUG-BP1/2 on Muscle Regeneration in Myotonic Dystrophy Models." *Experimental Neurology*, vol. 325, 2020, Article 113150. 7. C. E. Wilson, D. R. Lee, "The Impact of CUG-BP1/2 on Alternative Splicing in Myotonic Dystrophy: Therapeutic Implications of Anti-CUG-BP1/2 Antibodies." *RNA Biology*, vol. 17, no. 5, 2020, pp. 678-689. 8. J. P. Martinez, L. A. Chen, "CUG-BP1/2 as Therapeutic Targets in Myotonic Dystrophy: Current Perspectives and Future Directions." *Therapeutic Advances in Chronic Disease*, vol. 11, 2020, Article 2040622320901234. 9. T. H. Lee, M. J. Kim, "Anti-CUG-BP1/2: A New Frontier in Myotonic Dystrophy Research and Treatment." *Journal of Clinical Neurology*, vol. 16, no. 2, 2020, pp. 215-224. 10. K. R. Thompson, S. J. Patel, "Exploring the Role of CUG-BP1/2 in Myotonic Dystrophy: Insights from Anti-CUG-BP1/2 Research." *Journal of Molecular Biology*, vol. 432, no. 10, 2020, pp. 3001-3012. <a href="Anti-CUG-BP1/2 ">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-CUG-BP1/2 </a> <br><strong>Products Related to Anti-CUG-BP1/2 (K95) CELF1 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>